Neutralizing autoantibody against factor XIII A subunit resulted in severe bleeding diathesis with a fatal outcome - characterization of the antibody
- PMID: 27208811
- DOI: 10.1111/jth.13367
Neutralizing autoantibody against factor XIII A subunit resulted in severe bleeding diathesis with a fatal outcome - characterization of the antibody
Abstract
Essentials Autoantibody against factor XIII (FXIII) is a rare but severe acquired hemorrhagic diathesis. In an elderly patient, anti-FXIII-A antibody led to severe bleedings with fatal outcome. The neutralizing autoantibody bound to FXIII with high affinity (Ka≈10(9) m(-1) ). The dominant effect of the autoantibody was the inhibition of activated FXIII.
Summary: Autoantibodies may develop against the catalytic A subunit of factor XIII (FXIII-A) or the carrier B subunit (FXIII-B). Autoimmune FXIII-A deficiency was diagnosed in an elderly (75 years) patient with severe bleeding symptoms. The patient had 3% FXIII activity, and unmeasurable FXIII-A2 B2 and FXIII-A antigens in the plasma, whereas, in the platelet lysate, activity and FXIII-A antigen values were normal. As revealed by western blotting, FXIII antigen was present in the plasma, but the autoantibody interfered with the immunoassays. A mixing study indicated the presence of inhibitor with a titer of 63.2 Bethesda units (BU). The patient's IgG bound to FXIII-A2 B2 and to FXIII-A2 with equally high affinity (Ka in the range of 10(9) m(-1) ). It exerted a multiple inhibitory effect on FXIII activation/activity (IC50: 50 μg mL(-1) ). Immunosupressive therapy gradually decreased the autoantibody titer to 8.0 BU, but FXIII activity remained very low, and, owing to recurrent bleeding, the patient died.
Keywords: blood coagulation disorder; factor XIII; factor XIII deficiency; factor XIIIa; neutralizing antibody.
© 2016 International Society on Thrombosis and Haemostasis.
Similar articles
-
Severe bleeding diatheses in an elderly patient with combined type autoantibody against factor XIII A subunit; novel approach to the diagnosis and classification of anti-factor XIII antibodies.Haemophilia. 2017 Jul;23(4):590-597. doi: 10.1111/hae.13205. Epub 2017 Mar 26. Haemophilia. 2017. PMID: 28345289
-
Severe bleeding complications caused by an autoantibody against the B subunit of plasma factor XIII: a novel form of acquired factor XIII deficiency.Blood. 2009 Jan 15;113(3):723-5. doi: 10.1182/blood-2008-09-179333. Epub 2008 Oct 27. Blood. 2009. PMID: 18955560
-
[Autoimmune acquired coagulation factor XIII/13 deficiency caused by type Ab anti-FXIII-A autoantibody].Rinsho Ketsueki. 2023;64(12):1508-1513. doi: 10.11406/rinketsu.64.1508. Rinsho Ketsueki. 2023. PMID: 38220150 Japanese.
-
Auto- and alloantibodies against factor XIII: laboratory diagnosis and clinical consequences.J Thromb Haemost. 2018 May;16(5):822-832. doi: 10.1111/jth.13982. Epub 2018 Mar 23. J Thromb Haemost. 2018. PMID: 29460500 Review.
-
[Acquired autoimmune coagulation factor XIII/13 deficiency].Rinsho Ketsueki. 2020;61(7):799-808. doi: 10.11406/rinketsu.61.799. Rinsho Ketsueki. 2020. PMID: 32759568 Review. Japanese.
Cited by
-
Acquired factor XIII deficiency: A scoping review.Eur J Anaesthesiol Intensive Care. 2023 Sep 29;2(5):e0035. doi: 10.1097/EA9.0000000000000035. eCollection 2023 Oct. Eur J Anaesthesiol Intensive Care. 2023. PMID: 39916809 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials